Skip to main content
. 2022 May;11(5):694–709. doi: 10.21037/tau-22-312

Figure 4.

Figure 4

PFS was longer in patients who received primary kidney tumor resection. Local therapy for the metastatic site seemed to benefit patients in the IMDC favorable-risk group (A) but not those in the IMDC intermediate-risk group (B). IMDC, International Metastatic RCC Database Consortium; PFS, progression-free survival.